Brivaracetam controlled-release preparation and preparation method thereof

A technology of membrane control and excipient, applied in the field of anti-epileptic drug briracetam controlled-release tablet and its preparation, can solve the problems of solvent residual environment and pollution, etc.
CN111407738AInactive Publication Date: 2020-07-14JIANGSU ALICORN PHARMATECH CO LTD
8 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JIANGSU ALICORN PHARMATECH CO LTD
Publication Date
2020-07-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a brivaracetam oral controlled-release preparation and a preparation method thereof. The controlled-release preparation is a single-chamber osmotic pump controlled-release preparation, and is composed of a drug tablet core, a membrane-controlled coating system and a drug-release hole. The drug tablet core comprises 30-60wt% of brivaracetam, and the membrane-controlled coating accounts for 3-8 (w / w, %) of the total preparation. The controlled-release preparation disclosed by the invention has an in-vitro zero-level constant-speed drug release curve, can form a sphericalpreparation after water absorption swelling, and is not prone to being adhered to the wall of a digestive tract to cause too high local drug concentration.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to an antiepileptic drug briracetam controlled-release tablet and a preparation method thereof, which can be used for adjuvant treatment of partial seizures with or without secondary generalized seizures in adults and adolescent epilepsy patients aged 16 and above. Background technique

[0002] Briracetam is a racetam derivative with extensive antiepileptic activity and high safety. The drug can exert antiepileptic effect by binding to synaptic vesicle protein 2A (SV2A). More than 3,000 people have participated in clinical trials of brivaracetam, and provided some patients with more than 8 years of clinical experience. In 2016, it was approved for marketing in the European Union and the US FDA. The trade name is: BRIVIACT, a third-generation new epilepsy drug (levetiracetam and lacosamide) designed and developed by UCB Pharm in Belgium. International Patent Application Publication No. WO 01 / 62726 discloses 2-oxo-1-pyrrolidine der...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More